Forsun Pharma (01652): Henan Forsun received a capital increase of 300 million yuan.

Wisdom Financial News APP, Fosun Pharma (01652) announced that on June 18, 2026, investors (Nanyang Chantu and Henan Xisheng), Nanyang Hengsheng, Wealth Depot (HK) and target company Henan Fosen entered into a capital increase agreement. Investors are required to contribute a total of RMB 300 million in cash to subscribe for the additional registered capital of the target company, accounting for approximately 34% of the total enlarged registered capital of the target company after the capital increase. After the completion of the capital increase, the Company will indirectly hold approximately 66% of the total enlarged registered capital of the target company, and the target company will remain a subsidiary of the Company.